Treatment of non-small-cell lung cancer with chemotherapy and Sansheng Huatan Decoction

Abstract

Sansheng Huatan Decoction combined with chemotherapy is a better treatment for non-small-cell lung cancer as compared with chemotherapy.

Traditional Oriental Herbal Medicine and Natural Killer Cells for Cancer Patients: A Systematic Review and Meta-analysis

“…The information in these ten trials including incidence rate, severity, and concentrations of blood count indicated that adverse reactions reported were toxicities associated with conventional treatment that the participants in both groups received commonly, not associated with HM. Three trials reported no between‐group differences (Zhuang et al, ; Xie et al, ; Jiang et al, ), while seven trials found significant positive findings on combined HM‐conventional treatment group for partial adverse reactions comparing with control group (Xiao and Yang, ; Wu et al, ; Hou and Lu, ; Zhuang et al, ; Fang et al, ; Chan et al, ; Lin et al, ). The adverse reactions reported in both intervention and control groups were neutropenia, leukopenia, anemia, thrombocytopenia, nausea and vomiting, diarrhea, stomatitis, salivary gland change, anorexia, abdominal distension, hearing impaired, cutaneous change, neuropathy, fever, and hepatic, renal, and cardiac adverse reactions.…”

“…The proportions of NK cells increased in 12 studies, seven of which demonstrated statistical significance, in patients treated with HM plus conventional medicine compared with those treated with conventional medicine alone (Jia et al, ; Hou and Lu, ; Zhang et al, ; Fang et al, ; Jiang et al, ; Gao et al, ; Lin et al, ). There was a smaller decrease in absolute NK cell counts after conventional treatment combined with HM in two studies (Zhuang et al, ; Chan et al, ).…”

“…The RCT by Hou and Lu that did not report the reasons for dropout, and nine RCTs did not address the dropout rate had unclear attrition bias. Thirteen RCTs with the enumeration of pre‐specified outcomes had low ROB, two RCTs with inadequate selective under‐reporting of data in graphs to be included in a meta‐analysis had unclear ROB (Zhuang et al, ; Chan et al, ), and one RCT that investigated the NK cells in unprescribed partial number of patients in each group had high ROB for selective outcome reporting (Fang et al, ). For other sources of bias, the study by Chan et al prematurely terminated according to the unplanned interim analysis and was assessed as having unclear ROB.…”

“…Two studies were 3-arm trials (HM group vs. control group vs. combination group), while 14 studies were 2-arm trials (treatment group vs. control group). The RCTs included participants with different types of cancer: lung (Du et al, 2009;Zhang et al, 2007b;Fang et al, 2004;Lu et al, 2008), colorectal (Xiao and Yang, 2011;Wu et al, 2010;Li et al, 2000), hepatic (Hou and Lu, 2009;Gao et al, 2005;Lin et al, 2005), breast (Zhuang et al, 2012), nasopharyngeal (Xie et al, 2001), ovarian (Chan et al, 2011), and prostate cancer (Jia et al, 2013). Additionally, two RCTs had inclusion criteria with no specified cancer type (Zhuang et al, 2009;Jiang et al, 2001).…”

“…The information in these ten trials including incidence rate, severity, and concentrations of blood count indicated that adverse reactions reported were toxicities associated with conventional Abbreviations: ALP, alkaline phosphatase; ALT, alanine transaminase; APAAP, the alkaline-phosphatase anti-alkaline-phosphatase technique; AST, aspartate transaminase; C, control group; CBC, complete blood count; CE, carboplatin + etoposide; CF, cisplatin + 5-fluorouracil; CTX, chemotherapy; FAM, 5-fluorouracil + doxorubicin + mitomycin C; FC, flow cytometry; FOLFOX4, folinic acid + 5fluorouracil + oxaliplatin; GP, gemcitabine + cisplatin; Gr, grade; Hb, hemoglobin; MVP, mitomycin C + vinblastine + cisplatin; NCI-CTCAE, National Cancer Institute common terminology criteria for treatment that the participants in both groups received commonly, not associated with HM. Three trials reported no between-group differences (Zhuang et al, 2012;Xie et al, 2001;Jiang et al, 2001), while seven trials found significant positive findings on combined HMconventional treatment group for partial adverse reactions comparing with control group (Xiao and Yang, 2011;Wu et al, 2010;Hou and Lu, 2009;Zhuang et al, 2009;Fang et al, 2004;Chan et al, 2011;Lin et al, 2005). The adverse reactions reported in both intervention and control groups were neutropenia, leukopenia, anemia, thrombocytopenia, nausea and vomiting, diarrhea, stomatitis, salivary gland change, anorexia, abdominal distension, hearing impaired, cutaneous change, neuropathy, fever, and hepatic, renal, and cardiac adverse reactions.…”